env (a,b,c,a/e)/gag (c) dna vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2018 (NCT03409276)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04927585 | Phase 1 | Jul 8, 2021 | Harvard University, Immune Design, Worcester HIV Vaccine |
| NCT03409276 | Phase 1 | Mar 16, 2018 | National Institute of Allergy and Infectious Diseases (NIAID), University of Alabama, Birmingham, University of Pennsylvania |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Immune Design | For profit | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2018 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Worcester HIV Vaccine | For profit | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1